Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Immunoglobulin Light-chain Amyloidosis 3Multiple Myeloma 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2384Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1831Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1016Vincristine 964Cetuximab 945Trastuzumab 944Prednisone 941Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Focal Adhesion Protein-Tyrosine Kinases × Clear all
NCT05695508 2025-12-24

HD10/DSMMXX

University of Heidelberg Medical Center

Phase 2 Recruiting
160 enrolled
Plasma cell

Multiple Myeloma

NCT07079423 2025-07-23

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
35 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06935162 2025-05-25

Teclistamab in Previously Treated AL Amyloidosis

Peking Union Medical College Hospital

Phase 2 Recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT06699394 2025-04-24

Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis

Peking University People's Hospital

Phase NA Recruiting
20 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡